

Summary

Children 12 months of age in Quarter 2-2018

- National immunisation uptake rates, based on available data, were 93% for MenB₂, 90% for D₃, T₃, P₃, Hib₃, Polio₃, HepB₃, Rota₂ and MenC₁ and 89% for PCV₂.
- The national uptake rates increased by 1% in Quarter 2 compared to Quarter 1.
- MenC₁ at 12 months was 90% in Quarter 2 which is an improvement compared to 88% in Quarter 3 2017 and 89% in Quarter 1 2018 but is still 4-5% lower compared to Quarters 1-3 2017. This decline is a concern as it leaves children vulnerable to preventable meningococcal serogroup C infection.
- Among the Local Health Offices, the target uptake rate of 95% was reached in Longford/Westmeath and Dublin North Central for D₃, T₃, P₃, Hib₃, Polio₃, HepB₃, MenC₁, PCV₂ and MenB₂, Roscommon for PCV₂, MenB₂ and Rota₂, Mayo for MenB₂ and Rota₂ and in Clare, Tipperary NR/East Limerick, Tipperary South, Dublin South City, and Laois/Offaly for MenB₂.
- There are improvements in a number of LHOs including: WW (CHO6) uptake increased by 4-5% for all vaccines in Quarter 2 2018 compared to Quarter 1 2018, reversing previous downward trend, but are 7-8% lower compared to Quarter 2 2017. DNW (CHO9) uptake rates increased by 5-6% (to 91-94%) compared to Quarter 1. DNC (CHO9) uptake rates in Quarter 2 increased by 8-12% to 93% for Rota₂ and 95% for PCV₂ and MenB₂ and 96% for the remainder.

Children 24 months of age in Quarter 2-2018

- National uptake rates, based on available data, were 94% for D₃, T₃, P₃, Hib₃, Polio₃ and HepB₃, 93% for PCV_b, 92% for MMR₁, 91% for PCV₃, 90% for Hib_b, 88% for MenC_b and 86% for MenC₂.
- Compared to the previous quarter the national MenC₂ uptake rate declined by 2% nationally to 86%; with declines in 16 LHOs ranging from 1% to 7%.

MenC₂ was previously 86% in Quarter 3 2017 and was 88% in Quarter 4 2017 and Quarter 1 2018.

MenC₂ uptake was below 80% in two LHOs in Quarter 2 2018.

- D₃, T₃, P₃, Hib₃, Polio₃ and HepB₃ declined by 1% to 94%. This is the first time since 2010 that D₃, T₃, P₃, Hib₃ and Polio₃ did not reach the target of 95% at 24 months.
- While uptake of D₃, T₃, P₃, Hib₃, Polio₃ and HepB₃ were 94% uptake of the remaining vaccines in Q2 2018 are lower. Doses of these remaining vaccines are given at 12 and 13 months of age suggesting that parents are less likely to get the recommended vaccines for their children at this age.

Background

The national immunisation uptake statistics, based on available data, for Quarter 2 2018 are presented in this report. These immunisation uptake statistics relate to children at 12 (born between 01/04/2017 and 30/06/2017) and 24 (born between 01/04/2016 and 30/06/2016) months of age in Quarter 2-2018. These children were recommended the vaccines outlined in table 1. The immunisation schedule changed in 2016 for children born on or after October 1st 2016 after the National Immunisation Advisory Committee (NIAC) recommended meningococcal B (MenB) and rotavirus (Rota) vaccines (table 1). There is a change in timing of MenC with MenC now recommended at 6 months of age; in previous schedule MenC was recommended at 4 months (Table 1). A combined Hib/MenC dose and a PCV dose are now recommended at 13 months (Table 1).

For children at 12 months of age in Quarter 2 2018, immunisation uptake rates of three doses of vaccines against diphtheria (D_3), pertussis (P_3), tetanus (T_3), *Haemophilus influenzae* type b (Hib₃), polio (Polio₃), hepatitis B (HepB₃), two doses of pneumococcal conjugate vaccine (PCV₂), two doses of meningococcal serogroup B vaccine (MenB₂), two doses of rotavirus vaccine (Rota₂), one dose of meningococcal serogroup C conjugate vaccine (MenC₁) and one dose of BCG vaccine are reported.

For children at 24 months of age in Quarter 2 2018, immunisation uptake rates of three doses of vaccines against diphtheria (D₃), pertussis (P₃), tetanus (T₃), *Haemophilus influenzae* type b (Hib₃), polio (Polio₃), hepatitis B (HepB₃) and pneumococcal conjugate vaccine (PCV₃), two doses of vaccine against meningococcal group C (MenC₂) and one dose of vaccine against measles, mumps and rubella (MMR₁) are reported. One dose of vaccine against *Haemophilus influenzae* type b (Hib_b), one dose of meningococcal group C vaccine (MenC_b) and one dose of pneumococcal conjugate vaccine (PCV_b) given on or after 12 months of age are also reported.

The uptake statistics are also presented in this report by Community Healthcare Organisation (CHO) and Local Health Office (LHO). While there are 32 LHOs the immunisation uptake data for North Lee and South Lee are reported as a combined figure. The uptake rates presented here were rounded to zero decimal place. Cavan/Monaghan, Louth and Meath accurate data were not available in Q2 2018 and are not included in any of the figures/data in this report.

Age	Children born 01/07/2015 to 30/09/2016	Children born from 01/10/2016
Birth	BCG	BCG
2 months	DTaP/Hib/IPV/HepB (6 in 1) + PCV	DTaP/Hib/IPV/HepB (6 in 1) + PCV+ MenB+ Rota
4 months	DTaP/Hib/IPV/HepB (6 in 1) + MenC	DTaP/Hib/IPV/HepB (6 in 1) + MenB+ Rota
6 months	DTaP/Hib/IPV/HepB (6 in 1) + PCV	DTaP/Hib/IPV/HepB (6 in 1) + PCV+ MenC
12 months	MMR + PCV	MMR + MenB
13 months	MenC + Hib	Hib/MenC+ PCV

 Table 1. Primary childhood immunisation schedule for children born since 01/07/2015

Please note the primary immunisation schedule changed in 2015 for children born on or after 01/07/2015 and changed in 2016 for children born on or after October 1st 2016. Please see the HSE-National Immunisation Office (NIO) website at <u>www.immunisation.ie</u> for current and detailed information on the Irish primary childhood immunisation schedule and also recommended vaccinations for older children and adults

	on the mish primary childhood minumsation schedul
BCG	Bacille Calmette Guerin vaccine
DTaP	Diphtheria, Tetanus and acellular Pertussis vaccine
HepB	Hepatitis B vaccine
Hib	Haemophilus influenzae type b vaccine
IPV	Inactivated Polio Virus vaccine
MenB	Meningococcal group B vaccine
MenC	Meningococcal group C vaccine
MMR	Measles, Mumps and Rubella vaccine
PCV	Pneumococcal Conjugate Vaccine
Rota	Rotavirus oral vaccine

Immunisation uptake among children at 12 months of age in Quarter 2-2018 National

- National immunisation uptake rates were 93% for MenB₂ and 90% for D₃, T₃, P₃, Hib₃, Polio₃, HepB₃, Rota₂ and MenC₁ and 89% for PCV₂ (table 2). All figures/data presented here do not include the Cavan/Monaghan, Meath and Louth data as accurate data were not available for these LHOs at the time of data extraction.
- Compared to the previous quarter and based on available data, the national uptake rate in Q2-2018 for all vaccines (except BCG) increased by 1% (figure 1).
- This is the third cohort recommended the new immunisation schedule. The new immunisation schedule and changes in the schedule are shown in Table 1. MenB and Rota vaccines are now recommended. There is a change in timing of MenC with MenC now recommended at 6 months of age; in previous schedule MenC was recommended at 4 months (Table 1). A combined Hib/MenC dose and a PCV dose are now recommended at 13 months (Table 1).
- While MenC₁ uptake increased by 2% compared to Q4 2017 it is 4-5% lower than Quarters 1-3 2017. MenC previously declined in Q3 2010 for those at 24 months of age (and there was low uptake of Hib_b). These were the first cohort recommended hepatitis B and pneumococcal conjugate vaccines. In addition, there was a change in timing of the meningococcal serogroup C vaccines and *Haemophilus influenzae* type b booster vaccine for this cohort. The Q3 2010 report is <u>here</u>. The reasons for this decline and actions taken are described here.
- The BCG vaccine stock in all areas expired at the end of April 2015 so BCG vaccination clinics in HSE Clinics and Maternity hospitals have been postponed until new stock arrives. The licensed vaccine manufacturer has informed the HSE that BCG vaccine will not be delivered into Ireland until further notice and no alternative licensed supplier has been found. Please see https://www.hse.ie/eng/health/immunisation/news/bcg17.html for further information.

Community Healthcare Organisation (CHO)

• Among the CHOs, the uptake rates for PCV₂ ranged from 85% to 93%, Rota₂ ranged from 85% to 92%, D₃, T₃, P₃, Hib₃, Polio₃ and HepB₃ and MenC₁ranged from 88% to 93% and MenB₂ ranged from 89% to 95% (table 2). Note these comparisons include the CHO1 and CHO8 data which are incomplete.

Local Health Office (LHO)

- The immunisation uptake rates by LHO are shown in appendix 1.
- D₃, MenC₁, PCV₂, MenB₂ and Rota₂ immunisation uptake rates are mapped by LHO in figures 2-6.
- The immunisation uptake rates by Quarter and LHO are available <u>here</u> (tables) and <u>here</u> (graphs).

Changes in uptake in Q2 2018 compared to the previous quarter (unless stated otherwise)

- Among 28 LHOs i.e. excluding the CN/MN, LH and MH LHOs for Q1-2 2018 and Q3-Q4 2017:
 - D_3 uptake (figure 2) was >=90% in 17 LHOs in Q2 2018 compared to 11 of the LHOs in Q1 2018, 14 of the LHOs in Q4 2017 and 18 of the LHOs in Q3 2017.
 - MenC₁ uptake (figure 3) was >=90% in 17 of LHOs in Q2 2018 compared to 13 of the LHOs in Q1 2018, 15 of the LHOs in Q4 2017 and 27 of the LHOs in Q3 2017.
 - PCV_2 uptake (figure 4) was >=90% in 16 of the LHOs in Q2 2018 compared to 10 of the LHOs in Q1 2018, 13 of the LHOs in Q4 2018 and 16 of the LHOs in Q3 2017.
 - MenB₂ uptake (figure 5) was >=90% in 26 LHOs in Q2 2018 compared to 18 LHOs in Q1 2018 and 22 in Q4 2017.
 - Rota₂ uptake (figure 6) was >=90% in 16 LHOs in Q2 2018 compared to 10 LHOs in Q1 2018 and 11 in Q4 2017.
- Changes in uptake by LHO in Q2 2018 compared to Q1 2018 (except BCG):
 - o CHO1
 - CN/MN data were not available for Q2 2018
 - Donegal uptake of all vaccines increased by 1-3% compared to Q1 except for MenB₂ which declined by 1%. Donegal uptake of all vaccines had declined by 4-6% in Q1 compared to Q4 2017. In Q2 2018 uptake of Rota₂ was 82% compared to 86% for HepB₃ and 87% for the rest of the vaccines.
 - SO/LM Rota₂ uptake increased by 3% while remaining vaccines declined by 1-2%. In Q2 2018 uptake of Rota₂ was 91%, MenC₁ was 92% and 93% for the rest of the vaccines.
 - o CHO2
 - G uptake declined by 3-4%.
 - MO uptake declined by 1-2% except MenC₁ and MenB₂ which were unchanged.
 - RN uptake declined by 1-4% for all vaccines except Rota₂ which was unchanged.
 - o CHO3
 - CE uptake increased by 2-3% for all vaccines except MenC₁, MenB₂ and Rota₂. MenC₁ and Rota₂ at 91% were 2-4% lower compared to the remaining vaccines.
 - L uptake increased by 2% except Rota₂ which was unchanged.
 - L Rota₂ uptake was 88% compared to 94% for MenB₂ and 90% for the remainder.
 EL/TN uptake decreased by 1-2% except for PCV₂ which was unchanged and

MenB₂ which increased by 2%. In Q2 2018 Rota₂ uptake was 87% compared to 89% for $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$.

- o CHO4
 - NC uptake declined by 1-2% except for MenB₂ and Rota₂ which declined by 5%. PCV₂ and Rota₂ were 2% lower compared to D₃/T₃/P₃/Hib₃/Polio₃/HepB₃.
 NSL vaccine uptakes decreased by 2-4%.

PCV₂ is 2% lower compared to D₃/T₃/P₃/Hib₃/Polio₃/HepB₃.

- WC uptake increased by 1-5% in Q2 compared to Q1.
- KY uptake increased by 1-2%.
- PCV₂ and Rota₂ are 4% lower compared to D₃/T₃/P₃/Hib₃/Polio₃/HepB₃.
- CHO5 0
 - CW/KK MenC₁ declined by 1%, MenB₂ increased by 1%, Rota₂ increased by 2% while the remainder were unchanged.
 - TS uptake increased by 1% for all vaccines except MenB₂ which was unchanged.
 - WD uptake increased by 1-4% except MenC₁ which declined by 1%.
 - WX uptake increased by 1-3% except MenB₂ which was unchanged.

CHO6 0

- DS uptake rates increased by 1% or were unchanged.
- DSE uptake rates increased by 3-5%.
- WW uptake increased by 4-5% for all vaccines in Q2 2018 compared to Q1 2018, reversing previous downward trend, but are 7-8% lower compared to Q2 2017.
- CHO7 0
 - DSC uptake increased by 3-6% for all vaccines.
 - DSW uptake increased by 2-3% for all vaccines except Rota₂ was unchanged.
 - DW uptake increased by 1-3% for all vaccines. However, uptake is still 10% lower
 - for MenC₁ and 3% for D₃/T₃/P₃/Hib₃/Polio₃/HepB₃/PCV₂ compared to Q2 2017.
 - KE/WW uptake increased by 2-3% for all vaccines.

CHO8 0

- LS/OY uptake decreased by 1-2% for all vaccines.
- LD/WH uptake increased by 1-2% (to 95-96%) except Rota2 which decreased by 1% (to 91%).
- Q2 2018 data for Louth and Meath (and CN/MN) were not available.

CHO9 0

- DNW uptake increased by 5-6% (to 91-94%).
- DNC uptake increased by 8-12% to 93% for Rota₂ and 95% for PCV₂ and MenB₂ and 96% for the remainder.
- DN uptake increased by 1-3% except PCV₂ and Rota₂ were unchanged.

Table 2. Immunisation uptake (%) at 12 months in cohort born 01/04/2017-30/06/2017

Community Healthcare	No. in cohort [#]	BCG	$D_{3}T_{3}/P_{3}/$	HepB ₃	MenC ₁	PCV ₂	MenB ₂	Rota ₂
Organisation/LHO*			Hib _{3/} Polio ₃					
CHO1 (CN/MN ^{\$} , DL, SO/LM)	772	0.0†	89	89	89	89	89	85
CHO2 (G, MO, RN)	1387	0.0	91	91	92	92	94	92
CHO3 (CE, L, TN)	1236	0.0	91	91	90	91	95	89
CHO4 (NC, NSL, WC, KY)	2167	0.0	88	88	88	85	92	88
CHO5 (CW/KK, TS, WD, WX)	1576	0.4	90	90	90	89	93	90
CHO6 (DS, DSE, WW)	1214	0.0	89	89	89	89	91	89
CHO7 (DSC, DSW, DW, KE)	2342	0.0	90	90	90	90	92	91
CHO8 (LS/OY, LD/WH,LH ^{\$} , MH ^{\$})	1029	0.0†	93	93	93	93	95	91
CHO9 (DNW, DNC, DN)	2063	0.0	90	90	90	89	92	90
Ireland	13786†	0.05†	90	90	90	89	93	90

na = not available at this time

na = not available at this time *Shown in brackets are the LHOs in each CHO. Please see Appendix 3 to translate LHO codes. The geographical boundaries of the CHOs are shown at http://www.hse.ie/eng/services/publications/corporate/CHO_Chapter_1.pdf # The denominator/number in cohort varied slightly according to vaccine. D₃T₃ cohorts are shown here. †Number in cohort for BCG is 13,786. BCG data are unavailable for the former HSE North Eastern Area i.e. CN/MN, LH, MH; therefore CHO1 and CHO8 BCG data are incomplete. At the time of writing of this report the HSE continues to experience on-going delays with the supply of BCG vaccine. This continues to be a Europe wide issue. See point 5 on previous page regarding BCG vaccine stock in Ireland. *Cavan/Monaghan, Louth and Meath accurate data for all vaccines were not available in Q2 2018 and so are not included in this report.




Figure 1. National quarterly immunisation uptake rates at 12 months

X-axis ranges from 60-100%.

X-axis ranges from 60-100%. Since T₃ uptake is identical to D₃ uptake only D₃ uptake figures presented. The Q3-2008 MenC₃ uptake figure is based on data from six of the eight HSE Areas. The Q1-2009 HSE-Eastern Area D₃, P₃, T₃, Polio₃ and MMR₁ uptake figures exclude those born on the 31/03/2007. The Q3-2009 figures are incomplete as two HSE Areas were unable to provide data, two additional areas were unable to provide MenC₂ data and one additional area was unable to provide MenC₂ data. The Q4-2009 figures are incomplete as two HSE Areas were unable to provide data. The Q1-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as two HSE Areas in Q3 2009, for two HSE-Areas in Q4 2010, for five HSE-Areas in Q4 2010, Q1 2011 and Q2 2011, for six HSE-Areas in Q3 2011, for six HSE-Areas in Q3 2011 to Q4 2012. For Gata was not available for Galway and Roscommon the BCG denominator. Since Q1 2015 BCG data was available for Galway, Mayo and Roscommon LHOs. See page 2 regarding BCG vaccine stock in Ireland since April 2015. Q1 and Q2 2018 CN/MN, LH and MH data were not a data were not available.




Figure 2. D_3 immunisation uptake rates (%) by LHO, in those 12 months of age in Quarter 2-2018, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 3. MenC₁ immunisation uptake rates (%) by LHO, in those 12 months of age in Quarter 2-2018, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 4. PCV_2 immunisation uptake rates (%) by LHO, in those 12 months of age in Quarter 2-2018, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 5. $MenB_2$ immunisation uptake rates (%) by LHO, in those 12 months of age in Quarter 2-2018, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 6. Rota₂ immunisation uptake rates (%) by LHO, in those 12 months of age in Quarter 2-2018, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.

Immunisation uptake among children 24 months of age in Quarter 2-2018 National

- National uptake rates were 94% for D₃, T₃, P₃, Hib₃, Polio₃ and HepB₃, 93% for PCV_b, 92% for MMR₁, 91% for PCV₃, 90% for Hib_b, 88% for MenC_b and 86% for MenC₂ (table 3).
 All the figures/data described here for Q2 2018 do not include the Cavan/Monaghan, Meath and Louth data as accurate data were not available for these LHOs.
- Compared to the previous quarter national uptake rates in Q2-2018 for MenC₂ declined by 2%, D₃, T₃, P₃, Hib₃, Polio₃ and HepB₃ declined by 1%, Hib_b, MenC_b, PCV₃ and MMR₁was unchanged and PCV_b increased by 1% (figure 7). These comparisons are based on available data.
- Figure 7 presents the national uptake rates at 24 months for each vaccine from Q1-1999 to Q2-2018.

• This is the first time since 2010 that D₃, T₃, P₃, Hib₃ and Polio₃ did not reach the target of 95% at 24 months. Community Healthcare Organisations (CHOs)

• The target uptake of 95% was reached for D₃, P₃, T₃, Hib₃ and Polio₃ in six CHOs, in five for HepB₃, in one for Hib_b and PCV₃ and in none for the remainder (table 3).

Local Health Office (LHO)

- Immunisation uptake rates in children 24 months of age in Q2-2018 are presented by LHO in Appendix 2.
- D₃, Hib_b, MenC₂, MenC_b, PCV₃, PCV_b and MMR₁ immunisation uptake rates are mapped by LHO in figures 8-14.
- In Q2 2018 the target uptake of 95% was reached in 16 LHOs for D₃, T₃, P₃, Hib₃ and Polio₃, 14 for HepB₃, 8 for PCV_b, 5 for MMR₁, 3 for PCV₃, 2 for Hib_b, 1 for MenC₂ and none for MenC_b. In comparison in Q1 2018 the target uptake of 95% was reached in 17 LHOs for D₃, T₃, P₃, Hib₃ and Polio₃, 16 for HepB₃, 10 for MMR₁, 8 for PCV_b, 4 for Hib_b and PCV₃, 1 for MenC_b, and none for MenC₂.
- The immunisation uptake rates by Quarter and LHO are available <u>here</u> (tables) and <u>here</u> (graphs)
- Changes in uptake by LHO in Q2 2018 compared to Q1 2018:
 - MenC₂ declined in 16 LHOs by 1-7%, was unchanged in 4 LHOs and increased by 1-5% in 8 LHOs.
 - \circ Hib_b declined in 14 LHOs by 1-3%, were unchanged in one, and increased by 1-4% in 13 LHOs.
 - o MenC_b declined in 15 LHOs by 1-4%, were unchanged in one and increased by 1-4% in 12 LHOs.
 - o PCV_3 declined in 14 LHOs by 1-5%, were unchanged in five, and increased by 1-6% in 9 LHOs.
 - D₃ uptake declined in 13 LHOs by 1-5%, were unchanged in four and increased by 1-3% in 11 LHOs.
 - MMR₁ declined in 12 LHOs by 1-5%, were unchanged in 6 LHOs and increased by 1-8% in 10 LHOs.
 - $\circ~$ PCV_b declined in 7 LHOs by 1-4%, were unchanged in 10 LHOs, and increased by 1-7% in 11 LHOs.
 - o CHO1
 - Q2 2018 CN/MN (and Louth and Meath) data were not available.
 - Donegal MenC₂ declined by 6%, MenC_b declined by 3%, PCV_b declined by 2%, Hib_b, HepB₃, PCV₃ and MMR₁ declined by 1% while the remainder were unchanged. D₃/T₃/P₃/Hib₃/Polio₃ all reached the target of >=95%.

Uptake rates ranged from 79% (for MenC₂) to 95% (for D₃/T₃/P₃/Hib₃/Polio₃).

- SO/LM MenC₂ declined by 6%, PCV₃ declined by 5%, MenC_b declined by 4%, Hib_b and PCV_b declined by 3%, MMR₁ declined by 2% while the remainder were unchanged. D₃/T₃/P₃/Hib₃/Polio₃/HepB₃ all reached the target of >=95%.
 - Uptake rates ranged from 85% (for PCV₃) to 97% (for D₃/T₃/P₃/Hib₃/Polio₃).
- o CHO2
 - G uptake declined by 1-3%. D₃/T₃/P₃/Hib₃/Polio₃/HepB₃/PCV₃ were all >= target of 95%. Uptake rates ranged from 88% (for MenC_b) to 96% for (PCV₃).
 - Mayo uptake declined by 1-2% except for Hib_b and MenC₂ increased by 1%, MenC_b increased by 2% while MMR₁ was unchanged.
 D₃/T₃/P₃/Hib₃/Polio₃/HepB₃/PCV₃/PCV_b were all >= target of 95%.
 Uptake rates ranged from 89% (for MenC_b) to 96% for (PCV₃).
 - RN uptake increased by 1-4%. $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/MenC_2/PCV_3/PCV_b/MMR_1$ were all >= target of 95%. Uptake rates ranged from 94% (for Hib_b and MenC_b) to 99% (for $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/PCV_3/MMR_1$).
- o CHO3
 - CE MenC₂ uptake declined by 7%, PCV_b uptake increased by 2% while the remainder declined by 1-2%.
 D T (D (U) (D))
 - $D_3/T_3/P_3/Hib_3/Polio_3$ were all >= target of 95%.
 - Uptake rates ranged from 82% (for MenC₂) to 95% (for D₃/T₃/P₃/Hib₃/Polio₃).
 Limerick D₃/T₃/P₃/Hib₃/Polio₃/HepB₃ uptake declined by 5% while the remaining vaccines increased by 1-7%.
 - Vaccines increased by 1-7%. No vaccine reached the target of 95% in this quarter. Uptake rates ranged from 82% (for MenC₂) to 92% (for
 - $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/PCV_b/MMR_1$).

	-	TN/ELMenC ₂ and PCV ₃ uptake declined by 5%, $D_3/T_3/P_3/Hib_3/Polio_3/HepB_{3/}MMR_1$ declined by 3%, Hib _b declined by 1%, MenC _b which was unchanged and PCV _b increased by 3%.
		No vaccine reached the target of 95% in this quarter.
		Uptake rates ranged from 84% (for MenC ₂) to 94% (for
		$D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/PCV_b/MMR_1)$.
0	CHO4	
	•	NC $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$ uptake rates increased by 2%, increased by 1% for
		MMR_1 , were unchanged for PCV_3 and PCV_b , declined by 3% for $MenC_2$, declined by 2%
		for Hib _b and declined by 1% for MenC _b .
		$D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/Hib_b/PCV_b/MMR_1$ were all >= target of 95%.
		Uptake rates ranged from 91% (for MenC ₂) to 98% (for $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$). NSL uptake declined by 1-2% except MenC ₂ and PCV _b which was unchanged.
	_	$D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$ were all >= target of 95%.
		Uptake rates ranged from 87% (for MenC _b) to 95% for $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$).
	•	WC uptake increased by 2-8%.
		No vaccine reached the target of 95% in this quarter.
		Uptake rates ranged from 88% (for $MenC_b$) to 94% (for $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$).
	•	KY uptake declined by 1-3% except Hib_b which improved by 1% and $MenC_2$ was
		unchanged.
		No vaccine reached the target of 95% in this quarter. Uptake rates ranged from 85% (for MenC _b) to 93% (for $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$)
0	CHO5	Optake rates ranged from 85% (for Melic _b) to 95% (for $D_3/T_3/P_3/Ho_3/Polio_3/Hepb_3)_1$
0	•	CW/KK D ₃ /T ₃ /P ₃ /Hib ₃ /Polio ₃ /MenC _b increased by 1%, Hib _b and PCV ₃ declined by 1%,
		MenC ₂ declined by 2%, while HepB ₃ , PCV_b and MMR_1 were unchanged.
		No vaccine reached the target of 95% in this quarter.
		Uptake rates range from 83% (for MenC ₂) to 94% (for $D_3/T_3/P_3/Hib_3/Polio_3$).
	•	TS MenC ₂ declined by 4%, MenC _b declined by 1%, Hib _b , HepB ₃ , PCV ₃ , PCV _b and
		MMR ₁ were unchanged and $D_3/T_3/P_3/Hib_3/Polio_3$ increased by 1% to 99%.
		$D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/PCV_b/MMR_1$ were all >= target of 95%.
		Uptake rates ranged from 86% (for MenC ₂) to 99% (for D ₃ /T ₃ /P ₃ /Hib ₃ /Polio ₃).
	-	WD MenC ₂ uptake declined by 3%, MenC _b uptake declined by 2%, $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/Hib_b/PCV_3$ uptake declined by 1%, PCV _b was unchanged and
		MMR ₁ increased by 1%.
		No vaccine reached the target of 95% in this quarter.
		Uptake rates ranged from 83% (for MenC ₂) to 93% (for $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/$
		MMR ₁).
	•	WX uptake increased by 2-4%
		$D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/PCV_b$ were all >= target of 95%. Uptake rates ranged from 88% (for MenC ₂) to 96% (for $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$).
		Optake rates ranged from 88% (for MenC ₂) to 90% (for $D_3/T_3/T_3/H_{03}/T_{0103}/HepB_3)$.
0	CHO6	
-	•	DS uptake of all vaccines increased by 1-5% except MenC ₂ which was unchanged.
		$D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$ were all >= target of 95%.
		Uptake rates ranged from 83% (for MenC ₂) to 95% (for $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$).
	•	DSE MenC ₂ uptake decreased by 3% , Hib _b /MenC _b /MMR ₁ uptake decreased by 2% ,
		$D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$ by 1% while PCV ₃ and PCV _b which were unchanged.
		No vaccine reached the target of 95% in this quarter. WW uptake of all vaccines decreased by 2-5% with uptake rates ranging from 73% (for
		MenC ₂) to 83% (for $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$).
0	CHO7	
	•	DSC uptake rates increased by 2-6%.
		$D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$ all reached the target of >= 95%.
		Uptake rates ranged from 88% (for $MenC_2$ and $MenC_b$) to 95% (for
		D ₃ /T ₃ /P ₃ /Hib ₃ /Polio ₃ /HepB ₃).
	-	DSW Hib _b and MenC _b uptake increased by 2% , PCV _b increased by 1% , PCV ₃ decreased by 1% while the remainder were unchanged.
		$D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/PCV_b/MMR_1$ reached the target of >= 95%.
		Uptake rates ranged from 90% (for MenC ₂) to 96% (for D ₃ /T ₃ /P ₃ /Hib ₃ /Polio ₃ /HepB ₃).
	•	DW uptake rates increased by 1-2% except for PCV ₃ which declined by 2% and were
		unchanged for PCV_b and MMR_1 .
		No vaccine reached the target of 95% in this quarter.
		Uptake rates ranged from 83% (for $MenC_2/MenC_b$) to 93% for (for D (T (D (Hib (Belie (HapP))))
		$D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$). KE MenC ₂ declined by 3%, Hib _b and MenC _b uptake declined by 2% while the remainder
	-	KE Men C_2 declined by 5%, Ho_b and $MenC_b$ uptake declined by 2% while the remainder were unchanged.
		No vaccine reached the target of 95% in this quarter.
		Uptake rates ranged from 87% (for MenC ₂) to 94% (for $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$).
0	CHO8	
	•	LS/OY MenC ₂ uptake declined by 4%, MenC _b and PCV ₃ uptake declined by 3% while
		the rest declined by 2%.

No vaccine reached the target of 95% in this quarter. Uptake rates ranged from 88% (for MenC₂) to 94% (for D₃/T₃/P₃/Hib₃/Polio₃/HepB₃/Hib_b).

- LD/WH uptake increased by 1% for D₃/T₃/P₃/Hib₃/Polio₃/HepB₃/PCV₃ were unchanged for PCV_b and declined by 1% for MenC₂, MenC_b and MMR₁. Uptake rates ranged from 92% (for MenC₂/MenC_b) to 96% (for D₃/T₃/P₃/Hib₃/Polio₃/HepB₃/Hib_b). $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/Hib_b$ reached the target of >=95%.
- Q2 2018 accurate data for Louth and Meath (and CN/MN) were not available.

CHO9 0

- DNW uptake increased by 2-4% for all vaccines. $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/PCV_b/MMR_1\ reached\ the\ target\ of >=95\%\,.$ Uptake rates ranged from 93% (for $MenC_2/MenC_b$) to 98% for D₃/T₃/P₃/Hib₃/Polio₃/HepB₃.
- DNC uptake rates for all vaccines declined by 2-3% except for PCV₃ and PCV_b which were unchanged.

Uptake rates ranged from 91% (for MenC₂ and MenC_b) to 96% for D₃/T₃/P₃/Hib₃/Polio₃/HepB₃.

 $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/PCV_b$ reached the target of >=95%.

DN uptake declined by 2% for D₃/T₃/P₃/Hib₃/Polio₃/HepB₃, increased by 1% for Hib_b and PCV₃, increased by 2% for PCV_b and MMR₁ and increased by 3% for MenC₂ and MenC_b. Uptake rates ranged from 83% (for MenC₂ and MenC_b) to 91% for D₃/T₃/P₃/Hib₃/Polio₃/HepB₃.

No vaccine reached the target of 95% in this quarter.

Table 3. Immunisation uptake (%) at 24 months in cohort born 01/04/2016–30/06/2016

Community Healthcare Organisation/LHO	No. in Cohort*	D ₃ /T ₃ / P ₃ / Polio ₃	Hib ₃	Hib _b	HepB ₃	MenC ₂	MenC _b	PCV ₃	PCV _b	MMR ₁
CHO1(CN/MN ^s , DL, SO/LM)	791	96	95	90	94	82	87	85	91	91
CHO2 (G, MO, RN)	1428	96	96	92	96	91	89	97	94	94
CHO3 (CE, L, TN)	1273	94	94	90	93	83	88	90	93	92
CHO4 (NC, NSL,WC, KY)	2216	95	95	92	95	88	87	90	93	92
CHO5 (CW/KK,TS,WD,WX)	1656	95	95	90	95	85	88	91	94	94
CHO6 (DS, DSE, WW)	1323	90	90	83	90	80	81	87	88	88
CHO7 (DSC, DSW, DW, KE)	2492	95	95	89	95	87	88	90	93	92
CHO8 (LS/OY, LD/WH, LH ^s , MH ^s)	1015	95	95	95	95	90	91	91	94	94
CHO9 (DNW, DNC, DN)	2124	94	94	90	94	88	88	91	93	93
Ireland	14318	94	94	90	94	86	88	91	93	92

Please see Appendix 3 to translate LHO codes

na = not available

* As the denominator/number in cohort varied slightly according to vaccine D3T3 cohorts are shown here

^{\$}Cavan/Monaghan, Louth and Meath data were not available in Quarter 2 2018.




Figure 7. National quarterly immunisation uptake rates at 24 months

PEQUET 1. IVALIDITAL QUALTETLY IMPLIANTIAL SALIDON UPTAKE VATES AIT 24 MOOTINS Notes: The Q4-2005 MMR, figure is based on data from seven of the eight HSE-Areas. The Q1-2006 MMR, figure includes the HSE-Eastern Area figure that is an estimate only. The Q1-2007, Q3-2007, Q2-2008 and Q3-2008 Hib, figures are based on data from seven of the eight HSE Areas. In Q1-2008 the HSE-SE changed their Hib_b data extraction method compared to previous quarters; in Q1-2008 the uptake of Hib, in the HSE-SE was 83% compared to 53% in Q4-2007. The Q3-2008 MenC₃ figure is based on data from six of the eight HSE Areas. The Q1-2009 HSE-Eastern Area Hib, uptake figures exclude uptake figures exclude uptake figures exclude uptake figures from Dublin North. The Q4-2009 HSE-Eastern Area Hib, uptake figures exclude uptake figures from Dublin North. The Q4-2009 HSE-Eastern Area Hib, uptake figures also exclude uptake figures from Dublin North. The Q4-2009 HSE-Eastern Area Hib, uptake figures also exclude uptake figures from Dublin North. The Q4-2009 HSE-Eastern Area Hib, uptake figures also exclude uptake figures from Dublin North. The Q4-2009 HSE-Eastern Area Hib, uptake figures also exclude uptake figures from Dublin North. The Q4-2009 HSE-Eastern Area Hib, uptake figures also exclude uptake figures from Dublin North. The Q4-2009 HSE-Eastern Area Hib, uptake figures also exclude uptake figures from Dublin North. The Q4-2000 figures are based on data from seven of the eight HSE Areas. MenC₅ and PCV₆ data were only available for 6 the 8 HSE Areas from Q1 2012 to Q4 2014. MenC₆ and PCV₆ data were only available for 6 the 8 HSE Areas from Q1 2014. MenC₆ and PCV₆ data were unavailable.

Conclusions

The national uptake rate in Q2-2018 for MenC₁ at 12 months was 90% which is an improvement compared to 88% in Q4-2017 but is still 4-5% lower compared to Quarters 1-3 2017. This decline is a concern as it leaves children vulnerable to preventable meningococcal serogroup C infection. Meningococcal group B (MenB) and rotavirus (Rota) vaccine were introduced into the schedule for children born on or after 1st October 2016 and so were measured for the first time in the previous quarter, Q4 2017, among children at 12 months of age. In Q2 2018 national immunisation uptake rates were 93% for MenB₂ and 90% for Rota₂ compared to 90% for D₃, T₃, P₃, Hib₃, Polio₃, HepB₃ and MenC₁ and 89% for PCV₂.

In Q2-2018, national uptake rates at 24 months for D_3 , T_3 , P_3 , Hib₃, Polio₃ and HepB₃ declined by 1% to 94%. This is the first time since 2010 that D_3 , T_3 , P_3 , Hib₃ and Polio₃ did not reach the target of 95%. Uptake of the remaining vaccines in Q2 2018 are lower; doses of these remaining vaccines are given at 12 and 13 months of age suggesting that parents are less likely to get the necessary vaccines for their children at this age. MenC₂ was 86% in Q2; MenC₂ was previously 86% in Quarter 3 2017 and was 88% in Quarter 4 2017 and Quarter 1 2018.

Acknowledgements

HPSC would like to thank all those involved in childhood immunisation including the General Practitioners, Practice Nurses, HSE Areas, Public Health Nurses, Immunisation Co-ordinators, Specialists in Public Health Medicine, Surveillance Scientists and Systems Analysts for their assistance.




Figure 8. D_3 immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 2-2018, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 9. Hib_b immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 2-2018, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 10. MenC₂ immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 2-2018, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 11. MenC_b immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 2-2018, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 12. PCV_3 immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 2-2018, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 13. PCV_b immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 2-2018, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 14. MMR₁ immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 2-2018, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.

Appendix 1

							In	nmunisatio	n Uptake	(%)			
Community Healthcare Organisation (CHO)	LHO/CHO	No. in cohort for BCG*	No. in cohort for D ₃ T ₃ #	BCG*	D ₃ T ₃	P3	Hib ₃	Polio ₃	HepB ₃	MenC ₁	PCV ₂	MenB ₂	Rota
(6/10)	Cavan/Monaghan ^{\$}	na	na	na	na	na	na	na	na	na	na	na	na
	Donegal	468	468	0	87	87	87	87	86	87	87	87	82
	Sligo/Leitrim	304	304	0	93	93	93	93	93	92	93	93	91
	CHO1 Total*	772	772	0	89	89	89	89	89	89	89	89	85
	0	040		0	00			00		00	00	00	
	Galway Mayo	818 384	818 384	0	90 92	90 92	90 92	90 92	90 92	90 94	90 93	93 96	90 95
CHO2	Roscommon	185	185	0	92	92	92	92	92	94	93	96	95
	CHO2 Total	1387	1387	0	94 91	94 91	94 91	94 91	94 91	92	92	93 94	92
	Clare	369	369	0	94	94	94	94	93	91	93	95	91
сноз	Limerick	441	441	0	90	90	90	90	90	90	90	94	88
5	Tipperary NR/East Limerick	426	426	0	89	89	89	89	89	88	89	95	87
	CHO3 Total	1236	1236	0	91	91	91	91	91	90	91	95	89
	North Cork	308	308	0	87	87	87	87	87	87	85	90	85
CHO4	North South Lee	1273	1273	0	87	87	87	87	87	87	85	93	89
	West Cork	176	176	0	85	85	85	85	85	86	84	90	85
	Kerry	410	410	0	91	91	91	91	91	91	87	92	87
	CHO4 Total	2167	2167	0	88	88	88	88	88	88	85	92	88
СНО5	Carlow/Kilkenny	392	392	0.00	86	86	86	86	86	87	86	93	88
	South Tipperary	314	314	0.64	92	92	92	92	92	92	92	96	93
	Waterford	396	396	0.25	89	89	89	89	89	88	88	91	88
	Wexford	474	474	0.84	92	92	92	92	92	92	91	93	91
	CHO5 Total	1576	1576	0.44	90	90	90	90	90	90	89	93	90
	Dublin South	412	412	0	90	90	90	90	90	90	91	92	90
CHO6	Dublin South East	375	375	0	93	93	93	93	93	93	92	94	93
CHUO	Wicklow	427	427	0	84	84	84	84	84	85	84	86	84
	CHO6 Total	1214	1214	0	89	89	89	89	89	89	89	91	89
	Dublin South City	386	386	0	92	92	92	92	92	93	92	95	94
	Dublin South West	557	557	0	88	88	88	88	88	87	88	91	88
CHO7	Dublin West	553	553	0	87	87	87	87	87	86	87	90	90
	Kildare/West Wicklow	846	846	0	92	92	92	92	92	92	92	94	92
	CHO7 Total	2342	2342	0	90	90	90	90	90	90	90	92	91
	Laois/Offaly	563	563	0	92	92	92	92	92	92	92	95	91
	Longford/Westmeath	466	466	0	95	95	95	95	95	95	95	96	91
	Louth ^{\$}	na	na	na	na	na	na	na	na	na	na	na	na
	Meath ^{\$}	na	na	na	na	na	na	na	na	na	na	na	na
	CHO8 Total*	1029	1029	0	93	93	93	93	93	93	93	95	91
	Dublin North West	717	717	0	92	92	92	92	92	92	92	94	91
	Dublin North Central	398	398	0	96	96	96	96	96	96	95	95	93
CHO9	Dublin North	948	948	0	86	86	86	86	86	86	85	90	87
	CHO9 Total	2063	2063	0	90	90	90	90	90	90	89	92	90

na=not available

*BCG data were unavailable for Cavan/Monaghan, Louth and Meath *DeG data were unavailable for Cavan/Monaghan, Louth and Meath *The BCG vaccine stock in all areas expired at the end of April 2015 so BCG vaccination clinics in HSE Clinics and Maternity hospitals have been postponed until new stock arrives. The licensed vaccine manufacturer has informed the HSE that BCG vaccine will not be delivered into Ireland until further notice and no alternative licensed supplier has been found. Please see https://www.hse.ie/eng/health/immunisation/news/bcg17.html for further information.

#The denominator/number in cohort varied slighly according to vaccine. D_3T_3 cohort show n here.

⁶Q2 2018 Cavan/Monaghan, Louth and Meath data were not available Please note while North Lee and South Lee are two separate LHOs their combined immunisation uptake data are reported here.

Appendix 2

							Immun	isation Up	take (%)				
Community Healthcare Organisation (CHO)	LHO/CHO	No. in cohort for D ₃ T ₃ *	D ₃ T ₃	P3	Hib ₃	Hib _b	Polio ₃	HepB ₃	MenC ₂	MenC _b	PCV ₃	PCVb	MMR
(010)	Cavan/Monaghan ^{\$}	na	na	na	na	na	na	na	na	na	na	na	na
	Donegal	502	95	95	95	88	95	93	79	84	85	89	89
CHO1	Sligo/Leitrim	289	97	97	97	93	97	96	86	92	85	93	94
	CHO1 Total	791	96	96	95	90	96	94	82	87	85	91	91
								•.		•.		•	•••
	Galway	857	95	95	95	91	95	95	90	88	96	93	94
	Mayo	373	95	95	95	94	95	95	92	89	96	95	92
CHO2	Roscommon	198	99	99	99	94	99	99	96	94	99	98	99
	CHO2 Total	1428	96	96	96	92	96	96	91	89	97	94	94
	Clare	381	95	95	95	90	95	94	82	87	91	93	92
01100	Limerick	459	92	92	92	90	92	92	82	87	90	92	92
CHO3	Tipperary NR/East Limeri	433	94	94	94	92	94	94	84	89	90	94	94
	CHO3 Total	1273	94	94	94	90	94	93	83	88	90	93	92
	North Cork	291	98	98	98	95	98	98	91	92	93	95	96
	North South Lee	1324	95	95	95	91	95	95	88	87	90	94	92
CHO4	West Cork	170	94	94	94	93	94	94	89	88	90	93	94
	Kerry	431	93	93	93	91	93	93	86	85	89	91	90
	CHO4 Total	2216	95	95	95	92	95	95	88	87	90	93	92
		r											
	Carlow/Kilkenny	458	94	94	94	88	94	93	83	87	89	91	92
	South Tipperary	294	99	99	99	93	99	98	86	89	94	97	96
CHO5	Waterford	418	93	93	93	88	93	93	83	85	90	92	93
	Wexford	486	96	96	96	91	96	96	88	90	93	95	94
	CHO5 Total	1656	95	95	95	90	95	95	85	88	91	94	94
	Dublin South	433	95	95	95	86	95	95	83	84	92	94	92
	Dublin South East	443	93	93	93	86	93	93	85	86	90	91	90
CHO6	Wicklow	447	83	83	83	75	83	83	73	74	78	81	80
	CHO6 Total	1323	90	90	90	83	90	90	80	81	87	88	88
									,				
	Dublin South City	398	95	95	95	89	95	95	88	88	92	93	93
	Dublin South West	589	96	96	96	94	96	96	90	93	91	95	95
CHO7	Dublin West	595	93	93	93	86	93	93	83	83	85	89	88
	Kildare/West Wicklow	910	94	94	94	89	94	94	87	88	91	93	93
	CHO7 Total	2492	95	95	95	89	95	95	87	88	90	93	92
	Laois/Offaly	535	94	94	94	94	94	94	88	89	90	93	93
CHO8	Longford/Westmeath	480	96	96	96	96	96	96	92	92	93	94	94
	Louth ^{\$}	na	na	na	na	na	na	na	na	na	na	na	na
	Meath ^{\$}	na	na	na	na	na	na	na	na	na	na	na	na
	CHO8 Total	1015	95	95	95	95	95	95	90	91	91	94	94
	Dublin North West	737	98	98	98	94	98	98	93	93	94	96	96
	Dublin North Central	424	96	96	96	92	96	96	91	91	93	95	94
CHO9	Dublin North	963	91	91	91	85	91	91	83	83	88	90	90
	CHO9 Total	2124	94	94	94	90	94	94	88	88	91	93	93
			-										

na=not available *The denominator/number in cohort varied slighly according to vaccine. D₃T₃ cohorts show n here.

\$Q2 2018 CNMN (CH01), LH (CH08) and MH (CH08) data were not available. Rease note w hile North Lee and South Lee are two separate LH0s their combined immunisation uptake data are reported here.

Appendix 3

Local Health Office (LHO) Abbreviations (used in maps in this report)	Local Health Office (LHO)
CE	Clare
CN/MN	Cavan/Monaghan
CW/KK	Carlow/Kilkenny
DL	Donegal
DN	Dublin North
DNC	Dublin North Central
DNW	Dublin North West
DS	Dublin South
DSC	Dublin South City
DSE	Dublin South East
DSW	Dublin South West
DW	Dublin West
G	Galway
KE/WW	Kildare/West Wicklow
KY	Kerry
L	Limerick
LD/WD	Longford/Westmeath
LH	Louth
LS/OY	Laois/Offaly
MH	Meath
MO	Mayo
NC	North Cork
NSL*	North South Lee*
RN	Roscommon
SO/LM	Sligo/Leitrim
TN/EL	Tipperary North /East Limerick
TS	South Tipperary
WC	West Cork
WD	Waterford
WX	Wexford
WW	Wicklow

*Please note while North Lee and South Lee are two separate LHOs their combined immunisation uptake data are reported here